Study of ABBV-706 vs standard care for advanced small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with small cell lung cancer that has returned or is not responding to treatment.
- Your cancer worsened after at least one prior therapy that included platinum chemotherapy and a drug called tarlatamab.
- You are healthy enough to have an ECOG performance status of 0 or 1 (meaning you can walk and do daily activities).
- You have at least one tumor that can be measured on a scan.
- If you have brain tumors that are treated or stable without causing symptoms, you may qualify.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests a new drug, ZL-1310, against standard treatments for people with small cell lung cancer that has returned after initial therapy. The goal is to see if ZL-1310 works better than other options.
This trial tests a combination of a liposome-encased chemotherapy (irinotecan), a platinum drug, an immunotherapy, and a targeted therapy (anlotinib) as a maintenance treatment for extensive small cell lung cancer. The goal is to see if this approach helps keep the cancer from growing after initial successful treatment.
This Phase 2 trial tests how well two study drugs (and a combination of them) work in people with extensive-stage small cell lung cancer. It’s mainly for patients whose cancer has come back or who couldn’t tolerate at least some standard treatments, and it aims to see if treatment can shrink tumors and be tolerable.
This trial tests whether adding IBB0979 (an experimental immunotherapy) to standard chemotherapy (topotecan) works better than topotecan alone for people whose small cell lung cancer has returned or worsened after prior treatment. It aims to find a new option for patients who have limited options.
This trial tests a new drug called IBI3009 for people with advanced small cell lung cancer that cannot be removed by surgery. It aims to see how safe the drug is and how well it works against the cancer.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.